medicine: imexon

imexon description








Imexon (INN, trade name Amplimexon) is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative.

Tags

Keywords related to imexon

carfentanil retrovir aromasin ioglicic acid calcitriol lorfan salvia dibenzepin metrogel elcatonin herceptin cocaine layered double hydroxides ramatroban setiptiline telenzepine aristocort pegaspargase myotonachol sulfametoxydiazine arprinocid brotizolam allegra drug regadenoson azactam nortriptyline cytoxan catumaxomab budipine sulconazole alfentanil amitriptyline nardil letrozole aluminium hydroxide cedelizumab carbenoxolone paclitaxel lexapro dinoprost bontril mesulfen fluorometholone hetacillin lopirazepam crescormon norethandrolone taurolidine cortivazol allopurinol meglitinide


  • Related news


    AmpliMed Corporation Announces Promising 1-year Survival Data from
    3 /PRNewswire/ -- AmpliMed today reported one year survival results from a Phase I/II trial of its lead drug candidate, Amplimexon(R) (imexon for injection) ...
    Read full article

    Light bulb program.(DOMINICAN REPUBLIC)(Brief article) Article from
    Imexon, a joint venture of Canadian and Colombian firms, says it has a contract worth US$15.75 million to supply 3 million fluorescent light bulbs, ...
    Read full article

    US Oncology Affiliated Physicians Make a Strong Showing in ASCO
    Kansas City Cancer Center-South: PhaseI/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma Leukemia ...
    Read full article

    Article: Las Vegas Gallery exhibits unique mix of painting, sculpture
    by which AmpliMed's lead drug, Amplimexon(TM) (imexon inj may synergize with gemcitabine against human pancreatic cancer cells in vitro and in vivo. ...
    Read full article

    Arizona Cancer Center Receives $6.5M to Test New Anticancer Drugs
    Imexon was developed by Dorr; Evan M. Hersh, UA professor of The grant's second project, led by Dorr, will test Imexon in a clinical trial in ...
    Read full article

    Press Release: US Oncology Affiliated Physicians Make a Strong
    Kansas City Cancer Center-South: PhaseI/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma Leukemia ...
    Read full article

    AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of
    AmpliMed Corporation, a cancer therapeutics company, today announced that patient enrollment is underway in a Phase 2 trial of Amplimexon(R) (imexon for ...
    Read full article

    KOLD News 13 live, local and late breaking-Cancer Center Receives
    PX-12 and Imexon are drugs that target cancer-causing proteins. The cancer center says Imexon "first showed activity against multiple myeloma and is ...
    Read full article

    AmpliMed Corporation to Present Clinical Data From Three Clinical
    "A Phase I Study of Imexon Inj. Plus Gemcitabine as First-line Therapy for Advanced Pancreatic Cancer with Preclinical Mechanistic Study of Dose Limiting ...
    Read full article

    Press Release: AmpliMed Corporation Announces Promising 1-year
    3 /PRNewswire/ -- AmpliMed today reported one year survival results from a Phase I/II trial of its lead drug candidate, Amplimexon(R) (imexon for injection) ...
    Read full article

    Larger etanercept dose has no added benefit.(Across Specialties)(
    Article: Addition of imexon may improve chemotherapy for . The maximum tolerated dose of imexon was judged to be 1000 mg, as one patient in the highest ...
    Read full article